Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 901 - 910 of 1165

Rosiver (ivermectin)

Status:

Concluded without agreement

Manufacturer:

Galderma Canada Inc.

Indication:

Rosacea

Last updated May 23, 2018

Elelyso (taliglucerase alfa)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Gaucher disease

Last updated May 17, 2018

Lynparza (olaparib)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

Last updated May 15, 2018

Vectibix (panitumumab)

Status:

Negotiations were not pursued

Manufacturer:

Amgen Canada Inc.

Indication:

Left Sided Metastatic Colorectal Cancer

Last updated May 10, 2018

Kyleena (levonorgestrel)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Conception Control

Last updated April 20, 2018

VPRIV (velaglucerase)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Gaucher disease

Last updated April 16, 2018

Zinbryta (daclizumab beta)

Status:

Negotiations were not pursued

Manufacturer:

Biogen Canada Inc.

Indication:

Multiple Sclerosis, Relapsing

Last updated March 29, 2018

Zykadia (ceritinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated March 20, 2018

Glatect (glatiramer acetate)

Status:

Concluded with an LOI

Manufacturer:

Pendopharm, a division of Pharmascience Inc.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated March 1, 2018

Botox (onabotulinumtoxin a)

Status:

Concluded with an LOI

Manufacturer:

Allergan Inc.

Indication:

Multiple Indications

Last updated February 28, 2018